Treating HIV-infected individuals reduces their viral load, consequently increasing their survival time and decreasing their infectivity.It has been proposed that universal testing and treatment (i.e., universal ``test & treat'') could lead to HIV elimination and would be extremely cost-effective.It is now being debated whether to use a universal ``test and treat'' approach in the ``real-world'' as a prevention strategy to control HIV epidemics.However current modeling predictions of the impact, and cost-effectiveness, of universal ``test & treat'' strategies are based on an unrealistically short survival time for treated individuals.Here we use mathematical modeling and a longer, more realistic, survival time.We model the potential impact of a universal ``test & treat'' strategy in South Africa.Our results show that increasing the length of the survival time on treatment, although beneficial to individuals, reduces the probability of eliminating HIV and decreases the cost-effectiveness of using universal ``test & treat'' strategies.Therefore our results show that individual-level benefits and public health benefits will conflict when using ``test & treat'' strategies to reduce HIV transmission.
Citation: Bradley G. Wagner, Brian J. Coburn, Sally Blower. Increasing survival time decreases the cost-effectiveness of using "test & treat to eliminate HIV epidemics[J]. Mathematical Biosciences and Engineering, 2013, 10(5&6): 1673-1686. doi: 10.3934/mbe.2013.10.1673
Treating HIV-infected individuals reduces their viral load, consequently increasing their survival time and decreasing their infectivity.It has been proposed that universal testing and treatment (i.e., universal ``test & treat'') could lead to HIV elimination and would be extremely cost-effective.It is now being debated whether to use a universal ``test and treat'' approach in the ``real-world'' as a prevention strategy to control HIV epidemics.However current modeling predictions of the impact, and cost-effectiveness, of universal ``test & treat'' strategies are based on an unrealistically short survival time for treated individuals.Here we use mathematical modeling and a longer, more realistic, survival time.We model the potential impact of a universal ``test & treat'' strategy in South Africa.Our results show that increasing the length of the survival time on treatment, although beneficial to individuals, reduces the probability of eliminating HIV and decreases the cost-effectiveness of using universal ``test & treat'' strategies.Therefore our results show that individual-level benefits and public health benefits will conflict when using ``test & treat'' strategies to reduce HIV transmission.
| [1] | Science, 287 (2000), 650-654. |
| [2] | Curr. Drug Targets Infect. Disord., 3 (2003), 345-353. |
| [3] | Int. Stat. Rev., 62 (1994), 229-243. |
| [4] | Lancet, 373 (2009), 1077; author reply, 1080-1071. |
| [5] | N. Engl. J. Med., 365 (2011), 493-505. |
| [6] | PLoS ONE, 5 (2010), e11068. |
| [7] | JAMA, 301 (2009), 2380-2382. |
| [8] | Wiley Series in Mathematical and Computational Biology, John Wiley & Sons, Ltd., Chichester, 2000. |
| [9] | AIDS, 24 (2010), 729-735. |
| [10] | J. Acquir. Immune Defic. Syndr., 55 (2010), S116-121. |
| [11] | Lancet, 358 (2001), 404-409. |
| [12] | Clin. Infect. Dis., 52 (2011), 793-800. |
| [13] | Lancet, 373 (2009), 9-11. |
| [14] | Lancet, 373 (2009), 48-57. |
| [15] | PLoS ONE, 7 (2012), e30216. |
| [16] | Lancet, 357 (2001), 1149-1153. |
| [17] | Lecture Notes in Biomathematics, 56, Springer-Verlag, Berlin, 1984. |
| [18] | J. Infect. Dis., 198 (2008), 59-67. |
| [19] | Ann. Intern. Med., 155 (2011), 209-216. |
| [20] | Lancet, 368 (2006), 531-536. |
| [21] | (2007). |
| [22] | (2011). |
| [23] | Math. Biosci., 180 (2002), 29-48. |
| [24] | Lancet Infect. Dis., 2 (2002), 487-493. |
| [25] | AIDS, 24 (2010), 775-776. |
| [26] | Lancet, 376 (2010), 953-954. |
| [27] | PLoS ONE, 7 (2012), e41212. |